Table 2. Distribution of positive expression of EpCAM, CA9 and CD147 in the RCC patient cohort.

	I	II	III	IV	Total
CA9+	27/29 93.1%	18/19 94.7%	13/16 81.3%	4/6 66.7%	62/70 88.6%
CD147+	22/29 75.9%	15/19 79.0%	15/16 93.8%	6/6 100%	58/70 82.9%
EpCAM+	8/29 27.6%	3/19 15.8%	1/16 6.3%	1/6 16.7%	13/70 18.6%
CA9+ and/or CD147+	28/29 96.5%	19/19 100%	15/16 93.8%	6/6 100%	68/70 97.1%
CA9+ and/or CD147+ in EpCAM+ group	8/8 100%	3/3 100%	1/1 100%	1/1 100%	13/13 100%
CA9+ and/or CD147+ in EpCAM− group	20/21 95.2%	16/16 100%	14/15 93.3%	5/5 100%	55/57 96.4%